Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Avidity Biosciences Inc (RNA).
Avidity Biosciences, Inc. is set to discuss groundbreaking results from the MARINA-OLE™ trial on March 4, 2024, showcasing the effectiveness of del-desiran (AOC 1001) in reversing disease progression in myotonic dystrophy type 1 (DM1) patients. This promising data, highlighting improvements in myotonia, muscle strength, and daily activities, will be shared during an investor event and through a live webcast. In light of these findings, Avidity is preparing to launch the Phase 3 HARBOR™ trial, continuing to explore the therapeutic potential of del-desiran.
For detailed information about RNA stock, go to TipRanks’ Stock Analysis page.